Boston Partners’s PharMerica Corporation PMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-1,436,519
| Closed | -$42.1M | – | 807 |
|
|
2017
Q3 | $42.1M | Buy |
1,436,519
+60,232
| +4% | +$1.69M | 0.05% | 248 |
|
|
2017
Q2 | $36.1M | Buy |
1,376,287
+133,339
| +11% | +$3.28M | 0.05% | 264 |
|
|
2017
Q1 | $29.1M | Sell |
1,242,948
-40,955
| -3% | -$1.01M | 0.04% | 274 |
|
|
2016
Q4 | $32.3M | Buy |
1,283,903
+915,786
| +249% | +$23.1M | 0.04% | 265 |
|
|
2016
Q3 | $10.3M | Buy |
368,117
+192,101
| +109% | +$4.92M | 0.01% | 396 |
|
|
2016
Q2 | $4.34M | Sell |
176,016
-57,646
| -25% | -$1.43M | 0.01% | 513 |
|
|
2016
Q1 | $5.17M | Buy |
233,662
+35,843
| +18% | +$954K | 0.01% | 464 |
|
|
2015
Q4 | $6.92M | Hold |
197,819
| – | – | 0.01% | 441 |
|
|
2015
Q3 | $5.63M | Sell |
197,819
-34,387
| -15% | -$1.16M | 0.01% | 463 |
|
|
2015
Q2 | $7.73M | Buy |
232,206
+74,710
| +47% | +$2.29M | 0.01% | 437 |
|
|
2015
Q1 | $4.44M | Buy |
+157,496
| New | +$3.91M | 0.01% | 529 |
|
|
2014
Q1 | – | Sell |
-238,661
| Closed | -$5.13M | – | 765 |
|
|
2013
Q4 | $5.13M | Sell |
238,661
-55,771
| -19% | -$1.01M | 0.01% | 506 |
|
|
2013
Q3 | $3.91M | Buy |
+294,432
| New | +$3.97M | 0.01% | 527 |
|
Boston Partners's PMC Position: Q4 2017 in Review
Boston Partners sold out of PharMerica Corporation (PMC) in Q4 2017, closing a stake of 1,436,519 shares — an estimated $42.1M sold.
Boston Partners first reported a position in PMC in Q3 2013 and held it in 13 quarters. The position peaked at $42.1M in Q3 2017. 0 funds tracked by Wall St. Rank hold PMC as of Q4 2017.
- Boston Partners reported no remaining PharMerica Corporation position as of Q4 2017 after selling out during the quarter.
- Boston Partners sold 1,436,519 PharMerica Corporation shares in Q4 2017, an estimated $42.1M.
- Boston Partners first reported a position in PharMerica Corporation in Q3 2013 and held it in 13 quarters.
- Boston Partners's PharMerica Corporation position peaked at $42.1M in Q3 2017.
- 0 funds tracked by Wall St. Rank held PharMerica Corporation as of Q4 2017.
Based on Boston Partners's 13F filing for Q4 2017, filed 1 Feb 2018.